U.S. Software Stock News

Berkshire Hathaway has recently overhauled its equity portfolio under new CEO Greg Abel, exiting multiple positions while committing multibillion‑dollar capital to Alphabet and other technology and AI‑linked holdings. This sharper tilt toward concentrated technology bets marks a clear evolution from Warren Buffett’s prior approach and reshapes how investors may view Berkshire’s role in the AI economy. We’ll now examine how this increased emphasis on Alphabet and AI could influence Berkshire...

Marzetti (MZTI) has been in focus after reporting flat year on year revenue, missing analysts’ expectations on EPS and EBITDA, and seeing its share price fall 6.8% following the earnings release. See our latest analysis for Marzetti. Looking beyond the post earnings drop, Marzetti’s share price has recently shown a modest rebound, with a 30 day share price return of 5.9% but a year to date share price return that is down 29.41% and a 1 year total shareholder return that is down 34.29%. This...

Equity Residential stock has delivered a 16.8% total return over the past three years, while a fresh Discounted Cash Flow (DCF) intrinsic value estimate suggests the shares may still trade below what the underlying cash flows imply, and recent merger headlines add a new layer of uncertainty to that picture. The 16.8% three year return points to steady shareholder gains, rather than a sharp rerating that would clearly exhaust valuation upside. Expected revenue and operating income growth,...

HA Sustainable Infrastructure Capital (NYSE:HASI) issued $1 billion in green senior unsecured notes to fund eligible green projects. The company was added to the Russell 2000 Defensive Index and the Russell 2000 Value-Defensive Index. The new green financing is intended for both new and existing sustainable infrastructure projects. HA Sustainable Infrastructure Capital, trading at $38.63, is positioned at the intersection of listed equities and green infrastructure financing. The stock is...

In recent days, Intellia Therapeutics reported strong clinical progress for its gene-editing pipeline, including promising Phase 3 results and plans for a U.S. launch of its ATTR therapy Lonvo-z in 2027. These developments come amid high short interest and questions about valuation, funding needs, and commercial readiness, making the clinical momentum particularly important for reassessing the company’s risk-reward profile. We’ll now examine how Lonvo-z’s Phase 3 progress and 2027 U.S...

Why Lincoln National’s new $500 million bond issue matters for stock investors Lincoln National (LNC) has just completed a $500 million offering of fixed to fixed reset subordinated notes due 2056, giving the insurer a fresh pool of long dated capital that could influence how you think about the stock. See our latest analysis for Lincoln National. Against this backdrop, Lincoln National’s 1 day share price return of 2.49% and 30 day share price return of 4.62% sit alongside a year to date...

Keel Infrastructure (NasdaqGM:KEEL) has reported delays and cost overruns on a flagship project, contributing to substantial quarterly losses. The company is facing renewed regulatory scrutiny at the same time as it is being added to multiple Russell indexes. These developments raise questions about long term profitability and operational execution for Keel Infrastructure. Keel Infrastructure operates in a capital intensive sector where large projects, regulatory oversight, and index...

NextDecade (NEXT) has just been added to several Russell value benchmarks, including the Russell 2000 Value and Russell 3000 Value indexes. This shift can reshape how institutional investors track the stock. See our latest analysis for NextDecade. NextDecade’s recent index inclusions come after a sharp year to date share price return of 40.71%, even though the 1 year total shareholder return declined 15.32%. This suggests strong recent momentum but a mixed longer term experience. If you are...

BlackSky Technology (BKSY) is back in focus after a contract modification from the National Reconnaissance Office lifted the value of its AROS satellite program above $150 million, along with a new multi-year imaging services agreement. See our latest analysis for BlackSky Technology. Recent news around the AROS contract and new imaging work comes after a mixed year for BlackSky Technology. The share price is up 38.04% year to date, but the 30 day share price return declined 32.19%. The 3...

EMCOR Group (EME) has affirmed a regular quarterly cash dividend of $0.40 per share, payable on July 31, 2026, to stockholders of record on July 15, 2026, highlighting its ongoing capital return policy. See our latest analysis for EMCOR Group. Alongside the steady dividend, EMCOR Group’s recent index removals and earnings optimism have coincided with a share price of $804.33. This reflects a 7 day share price return that is down 5.06%, but a 1 year total shareholder return of 48.74%,...

In late June 2026, BioAge Labs began dosing participants in QUELL-CV, a Phase 2 proof-of-concept trial of its oral NLRP3 inhibitor BGE-102 for cardiovascular risk reduction, following earlier Phase 1 data showing strong hsCRP reductions and good tolerability. This step advances BioAge’s pipeline from early safety testing toward assessing real-world cardiovascular outcomes, sharpening investor focus on its inflammation-targeted approach to heart disease. Next, we’ll explore how initiating the...

Anyone interested in Viemed Healthcare, Inc. ( NASDAQ:VMD ) should probably be aware that the Independent Director...

We wouldn't blame Vaxcyte, Inc. ( NASDAQ:PCVX ) shareholders if they were a little worried about the fact that Grant...

First Financial Bancorp (FFBC) stock has been in focus after the bank reported quarterly revenue of $265.8 million, which was 26.1% higher than a year earlier and 3.1% above analyst expectations. See our latest analysis for First Financial Bancorp. First Financial Bancorp’s recent earnings beat has coincided with strong momentum, with a 15.5% 1 month share price return and a 38.2% year to date share price return. The 3 year total shareholder return of 90.9% points to a solid longer term...

The Supreme Court’s backing of Federal Reserve independence, alongside persistent 4.1% inflation and Iran war related oil disruptions, has kept expectations for quick rate cuts in check and supported confidence in the U.S. dollar. A firm dollar can reshape winners and losers, affecting costs, overseas earnings, and balance sheets in different ways. For investors trying to position around this, one practical approach is to focus on large, financially solid companies that may handle prolonged...

Ouster (OUST) has moved into the spotlight after a series of manufacturing and partnership announcements around its Rev8 lidar platform and fresh BABA compliance that opened doors to federally funded infrastructure projects. See our latest analysis for Ouster. That enthusiasm has shown up clearly in Ouster’s trading, with the 90 day share price return of 207.95% and year to date share price return of 156.82%. The 1 year total shareholder return of 180.47% and very large 3 year total...

Bath & Body Works (BBWI) drew fresh investor attention after announcing a partnership with Ulta Beauty that will place a curated product assortment in more than 600 Ulta stores and on Ulta.com. See our latest analysis for Bath & Body Works. For context, Bath & Body Works’ 30 day share price return of 20.08% and 90 day share price return of 20.46% point to improving momentum, even though the 1 year total shareholder return is down 29.04% and longer term returns are also negative. If this Ulta...

Recent analyst coverage has put Federal Agricultural Mortgage (AGM) back in focus, highlighting its multi segment business model and consistent operational execution as investors reassess mortgage related stocks in a period of high rates. See our latest analysis for Federal Agricultural Mortgage. Those themes are showing up in the share price, with Federal Agricultural Mortgage’s 30 day share price return of 13.88% and 90 day share price return of 35.14% at a last close of $203.11, while the...

The Humana Foundation, the philanthropic arm of Humana Inc., recently committed over US$12.20 million in 2026 grants to support emotional well-being programs and research targeting loneliness, depression, and social isolation among seniors and veterans across multiple states. While these grants highlight Humana’s broader role in senior health, recent analyst coverage instead focuses on its Medicare Advantage revenue outlook and premium valuation as key drivers of investor interest. Next,...

Chemours (CC) stock is in focus after the company agreed to a regulatory settlement over PFAS discharges, committing to a US$22.5 million civil penalty and US$90 million of long term mitigation projects. See our latest analysis for Chemours. The PFAS settlement landed after a strong run for Chemours, with the share price up 64.41% year to date at US$20.14. However, recent 30 day and 7 day share price returns of 9.77% and 4.87% respectively indicate that momentum has cooled and reflect longer...

CF Industries Holdings (CF) is drawing fresh attention as tight global nitrogen fertilizer supply, geopolitical disruptions and constrained natural gas availability intersect with higher production costs, keeping industry fundamentals in sharp focus for investors. See our latest analysis for CF Industries Holdings. Over the past year, CF Industries Holdings has seen firm positive momentum, with the share price up 35% year to date and a 1 year total shareholder return of 17.72%. This comes...

Molina Healthcare (MOH) is in focus after new 2025 risk adjustment figures from the Centers for Medicare & Medicaid Services pointed to higher than expected payments for the company, alongside fresh index reclassifications and value-focused research coverage. See our latest analysis for Molina Healthcare. The recent risk adjustment update and index reshuffling come at a time when Molina Healthcare’s share price momentum has been strong, with a 30 day share price return of 26.9% and a 90 day...

In late June 2026, Absci Corporation reported positive interim Phase 1 data from its HEADLINE trial of ABS-201 for androgenetic alopecia, showing favorable safety, an estimated half-life of at least 65 days, and progression into multiple ascending dose cohorts, while also completing a US$100.00 million follow-on equity offering of 13,495,277 common shares at US$7.41 each. The combination of encouraging early data for a long-acting, antibody-based hair loss therapy and fresh equity capital...

W. R. Berkley (NYSE:WRB) has announced the resignation of Executive Vice President Lucille Sgaglione. The company has appointed John Enright as president of Berkley Specialty London. These leadership moves affect a key business segment that draws attention from investors tracking executive decision making. W. R. Berkley enters these leadership changes with its stock at $70.66 and a long term return of 134.5% over the past 5 years. Over the past 3 years, the stock is up 92.2%, while the 1...